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data on mRNA expression showed that allograft cartilage tissues express
cartilage speciﬁc markers.
Conclusions: The colonization of human viable knee and ankle allografts
by recipient cells was investigated by genetic typing and mRNA
expression. There is an evidence of persistence of donor cells particularly
in knee allografts. This event is rare in ankle allografts, where the
prevailing presence of host DNA suggests the ingrowth of recipient cells
into the allograft, presumably migrating from the subchondral bone, in
accordance with histological ﬁndings. The observed synthesis of cartilage
speciﬁc RNAs in some of the analysed samples argues for the acquisition
of a chondrocyte-like phenotype by some of these cells.
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Osteoarthritis (OA) involves pathological change in all joint tissues,
including cartilage degradation and synovitis. Synovial changes are
associated with pain, while cartilage loss is a major indication for
joint replacement. Cycloxygenase-2 (PTGS2) and inﬂammatory cytokines
(IL6, TNF) are implicated in pain and increasing degradative enzymes
and cartilage breakdown. A Cochrane study suggested positive clinical
beneﬁts of intra-articular hyaluronan (HA), despite its brief joint
residency time. An amide-derivative of HA (HYMOVIS™) with increased
joint retention was superior to native HA in improving gait, reducing
synovial hyperplasia and cartilage MMP13 expression in a sheep OA
model. To elucidate the mechanism of the improved in vivo effects with
the chemically modiﬁed HA, the effects of HYMOVIS™ on chondrocytes
and synoviocytes from OA patients were evaluated.
Chondrocytes (HAC, n = 6) and synoviocytes (HSF, n = 6) were isolated
from OA patients at the time of knee replacement. HYMOVIS™ or native
HA (0, 0.5, 1.0 or 1.5mg/mL) was added to primary HAC or early passage
HSF with interleukin-1b (IL1b, 2 ng/mL). Cultures were terminated
30 minutes later for Bioplex® quantitation of phosphoproteins (p-JNK,
p-NFúB, p-p38), or 24 hours later for RNA isolation and analysis of gene
expression by real time RT-PCR, and measurement of MMP13 activity in
the media. Only statistically signiﬁcant results are reported.
In both HAC and HSF IL1b increased expression of MMP1, MMP13, PTGS2,
IL6 (>100fold), all phosphoproteins (3–10fold) and MMP13 activity. Cell
speciﬁc effects were seen with IL1b increasing expression of ADAMTS4
in HAC; ADAMTS5 in HSF (~10fold); and causing a 2–3fold reduction of
mRNA for COL2A1 and ACAN in HAC and COL1A1 in HSF.
In both cell types, HYMOVIS™ added with IL1b decreased MMP13,
ADAMTS4, ADAMTS5, PTGS2, IL6 expression, normalized matrix protein
expression, but had no effect on phosphoproteins. Cell-type speciﬁc
effects included decreased MMP1 expression only in HSF, and reduced
MMP13 activity only in HAC. In HAC, HYMOVIS™ preincubation was
superior to simultaneous addition in reducing ADAMTS, MMP, PTGS2,
and IL6 expression, but it also inhibited expression of TIMP1 and TIMP3,
and abrogated the rescue of COL2A1 and ACAN expression. There was a
less dramatic effect of HYMOVIS™ preincubation on gene expression in
HSF compared with HAC.
These results demonstrated a signiﬁcant beneﬁcial effect of the
HA derivative, HYMOVIS™, on both synoviocyte and chondrocyte
metabolism in vitro. This suggests HYMOVIS™ may have broader
OA disease modifying actions and clinical beneﬁt by reducing the
negative effects of degradative enzymes and inﬂammatory cytokines
in comparison to native HA.
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EFFECTS OF SURGERY AND POST-OPERATIVE INTRA-ARTICULAR
CORTICOSTEROIDS ON SYNOVIAL FLUID COLLAGEN BIOMARKERS
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Purpose: Little is known about collagen metabolism in the joint after
surgery and how anti-inﬂammatory drugs affect this metabolism. The
purpose of this study was to investigate the effects of arthroscopic
surgery and post-surgical intra-articular administration of triamcinolone
acetonide (TA) on collagen synovial ﬂuid biomarkers using an animal
model of osteoarthritis. We hypothesized that collagen synthesis and
degradation would increase in synovial ﬂuid after arthroscopic removal
of osteochondral fragments, and that there would be greater collagen
degradation in the TA treated group than in saline controls.
Methods: In 7 normal adult Quarter Horses an osteochondral fragment
was arthroscopically created on the dorsal medial aspect of the ﬁrst
phalanx in one randomly chosen metacarpophalangeal joint (MCPJ).
MCPJ synovial ﬂuid was collected on weeks 0 (fragment creation), 16
(fragment removal), 17, 18, and 20. After ﬂuid collection on week 17,
horses were divided into 2 treatment groups: (1) horses (n = 4) that
received 1mL TA (10mg) and (2) horses (n = 3) that received 1mL saline
injected into the MCPJ from which the fragment was removed. Effects of
surgery and TA treatment were evaluated in week 18 and 20 samples.
Injured MCPJ synovial ﬂuid CPII, C12C, C2C (IBEX Technologies), and CTXII
(IDS/Nordic) concentrations were evaluated using commercially available
ELISAs previously validated for equine use. Synovial ﬂuid biomarker
concentrations for all weeks were compared to each other using unpaired
t-tests. P< 0.05 was considered signiﬁcant.
Fig. 1. Mean±SD synovial ﬂuid biomarker concentrations for CP II (A),
C12C (B), C2C (C), and CTX II (D). Week 0 = osteochondral (OC) fragment
creation; week 16 = OC fragment removal (Sx); week 17 = 1 week
post OC fragment removal followed by intra-articular injection (arrow –
Tx Admin) of either triamcinolone acetonide (TA) or saline; week 18 =
2 weeks post OC fragment removal and 1 week post TA (black bar) or
saline (gray bar) injection; week 20 = 4 weeks post OC fragment removal
and 3 weeks post TA (black bar) or saline (gray bar) injection. Different
letters indicate signiﬁcance differences (P < 0.05).
Results: Sixteen weeks after creation of an osteochondral fragment,
concentrations of CPII, C2C, C12C, and CTX II all signiﬁcantly increased
